Our Focus on Immuno-Oncology
In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.
The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.
NEWS RELEASE
Devonian Reports Positive Results in MASH Liver Study
In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse. Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…
EVENT
SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology from May 9th (Thu) to 11th (Sat). In the Exhibition section, we will introduce our drug efficacy evaluation study services using our original MASH (NASH)-hepatocarcinoma model, STAM™ mouse, as well as other…
Sig Transduct Target Ther.,
“The AKAP12-PKA axis regulates lipid homeostasis during alcohol-associated liver disease” (Signal Transduct Target Ther., DOI: 10.1038/s41392-025-02202-1, 2025)
STAM™ model
Our STAM™ model is a model that recapitulates the same disease progression as human MASH/HCC.
